Literature DB >> 11586009

Topical metronidazole does not abate UVB-induced erythema.

M Guarrera1, C Brusati, A Rebora.   

Abstract

BACKGROUND: The capacity of topical metronidazole to reduce erythema severity scores in rosacea has been attributed to its anti-inflammatory activity.
METHODS: Nine healthy subjects were irradiated on three 1-cm(2) areas on their volar forearm with 2 MEDs of UVB. Twenty-four hours later, one of the irradiated areas was treated daily with metronidazole 1% vanishing cream, one with the vehicle only and the third was left untreated (control). The intensity of erythema was measured, at 24, 48, 72 and 96 h after irradiation, by a Chromameter CR200 (Minolta, Japan) and expressed in the L*a*b* system. The a* parameter was taken as the measure of redness.
RESULTS: Overall, redness diminished over time in a linear way, but treatments did not influence it significantly.
CONCLUSION: In our vehicle, metronidazole 1% cream failed to abate the UVB-induced erythema. An activity other than the anti-inflammatory one should be suggested to explain the topical metronidazole efficacy in rosacea. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586009     DOI: 10.1159/000051725

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  1 in total

1.  Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.

Authors:  J Fowler; M Jarratt; A Moore; K Meadows; A Pollack; M Steinhoff; Y Liu; M Leoni
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.